INTRODUCTION
============

Hepatocellular carcinoma (HCC) is one of the few cancers that can be diagnosed solely using noninvasive imaging studies. Major contemporary guidelines proposed by the American Association for Study of Liver Diseases, Liver Imaging Reporting and Data System (LI-RADS), European Association for the Study of the Liver, Asian Pacific Association for the Study of the Liver, Korean Liver Cancer Association-National Cancer Center (KLCA-NCC), and Japanese Society of Hepatology all allow confirmative diagnosis of HCC by identifying the hallmarks of the tumor, i.e., arterial phase hyperenhancement (APHE) and portal venous or delayed phase washout, on multiphasic CT and MRI using extracellular or liver-specific contrast agents ([@B1][@B2][@B3][@B4][@B5][@B6]). The diagnostic algorithms of these guidelines recommend performing multiphasic CT or MRI to establish a diagnosis of HCC in nodules discovered during surveillance, typically with ultrasound, while CT and MRI are also endorsed in Eastern guidelines for certain groups of patients. Should these nodules lack hallmarks of HCC and thus are deemed indeterminate, various options, including follow-up imaging, a second round of imaging with an alternative modality or contrast agent, or biopsy, are possible for further characterization ([@B1][@B2][@B3]).

Among indeterminate nodules, arterial-enhancing nodules that do not washout are often encountered on multiphasic CT in cirrhotic livers and impose a diagnostic challenge. In liver cirrhosis, hepatic parenchymal distortion and blood flow redistribution result in arterial-enhancing lesions that are not HCC, particularly arterioportal (AP) shunts ([@B7]). Because up to 60% of small HCCs may not demonstrate washout ([@B8][@B9]), such arterial enhancing-only nodules require sequential diagnostic imaging either immediately or in follow-up ([@B1][@B2][@B3]). Although there is yet no consensus suggesting which imaging modality should be used for this purpose, many centers in Eastern countries prefer gadoxetic acid (Eovist or Primovist; Bayer HealthCare, Berlin, Germany)-enhanced MRI because of its high sensitivity in hepatobiliary phase imaging (HBP) ([@B10][@B11][@B12]). However, this technique is expensive, and because dynamic imaging has already been obtained from multiphasic CT, it is unclear whether gadoxetic acid-enhanced MRI needs additional dynamic imaging. With this, we hypothesized that adding a non-contrast MRI protocol omitting dynamic imaging and HBP may have adequate diagnostic value. If non-contrast MRI with shortened sequences could be used to characterize indeterminate hypervascular lesions detected on multiphasic CT in at-risk patients, the need to perform full-sequence MRI may be reduced. Therefore, this study aimed to determine the feasibility of non-contrast MRI for characterizing nodules with arterial hypervascularity alone detected on multiphasic CT in patients at risk of HCC.

MATERIALS AND METHODS
=====================

This retrospective study was approved by the Institutional Review Board of three institutions (Ajou University Hospital, Asan Medical Center, and Gil Medical Center), and the requirement for written informed consent was waived. The present report constitutes a substudy based on data from a multicenter study that has been registered on the domestic trial registry of the Republic of Korea (cris.nih.go.kr: KCT0003221).

Patient Selection
-----------------

We retrospectively searched 844 consecutive patients with chronic liver disease who underwent gadoxetic acid-enhanced MRI to evaluate indeterminate, arterial-enhancing nodules detected during multiphasic CT surveillance less than 3 months apart while attending the liver unit at Ajou University Hospital and Gil Medical Center between January 2015 and March 2017, and at Asan Medical Center between January 2013 and December 2013. A further selection identified 670 nodules in 591 patients according to the following inclusion criteria: 1) discrete round or ovoid nodules with APHE on multiphase CT without prior treatment for HCC; 2) nodules with no or equivocal washout in the portal venous and delayed phases ("equivocal washout" was defined as any discrepancy in the interpretation of washout appearance between two readers during the later formal image review); 3) nodules 0.5--2.0 cm in diameter numbering three or less per patient; and 4) nodules that were not typical hemangiomas (nodules with marked T2 hyperintensity equivalent to the intensity of cerebrospinal fluid and the usual peripheral globular, progressive centripetal enhancement pattern) or AP shunts (subcapsular lesions with wedge-shaped arterial enhancement of straight border without washout) ([@B4][@B7]). If there were four or more suspicious nodules in the patient, we included only the three largest nodules. We excluded 348 patients who had been treated using transcatheter arterial chemoembolization or radiofrequency ablation and thus lacked a pathological diagnosis, as well as 149 patients with insufficient follow-up (\< 18 months). Finally, 151 nodules in 134 patients were included ([Fig. 1](#F1){ref-type="fig"}). The nodules were selected and annotated by study coordinators from each center (all with more than 7 years of experience in hepatic imaging) who were not involved in the image analysis. Of these nodules, 33 nodules had been included in a previous study ([@B13]).

Imaging Protocols
-----------------

### CT Techniques

All CT examinations were performed using various multidetector CT scanners (SOMATOM Sensation 64, SOMATOM Definition, or SOMATOM Definition Flash; Siemens Healthineers, Forchheim, Germany). Acquisition protocols varied between centers, with a reconstruction thickness between 2 mm and 5 mm. All multiphasic CT examinations comprised unenhanced, late hepatic arterial (30--35 seconds), portal venous (75--90 seconds), and delayed (3 minutes) phases. In total, 1.5--2 mL/kg of iodine contrast media, with an iodine concentration of 300 g/L, was injected using a power injector at a rate of 3--4 mL/s, not exceeding 150 mL in total volume.

### MRI Techniques

MRI examinations were performed using 1.5T and 3T scanners at Asan Medical Center (Magnetom Avanto 1.5T and Skyra 3T; Siemens Healthineers), 3T scanners at Gil Medical Center (Verio 3T and Skyra 3T; Siemens Healthineers), and 1.5T and 3T scanners at Ajou University Hospital (Signa HDx 1.5T and Discovery MR750w 3T; GE Healthcare, Milwaukee, MI, USA). HBP was obtained 15--20 minutes after a bolus injection of 0.025 mmol/kg (0.1 mL/kg) gadoxetic acid.

Image Analysis
--------------

CT and MR images were anonymized, randomized, and independently reviewed by two board-certified abdominal radiologists, each with more than 7 years of experience in hepatic imaging. Images from each reviewer\'s own center were reviewed on-site and those from other centers were remotely accessed. The largest diameter and location of each nodule according to the Couinaud classification were recorded. In four MRI sequences of the sequential MRI examination, the presence of the following eight imaging features that favor a diagnosis of HCC were evaluated in each nodule ([@B12][@B14][@B15][@B16]): 1) mild-to-moderate hyperintensity on T2-weighted imaging (T2WI); 2) hyperintensity on diffusion weighted imaging (DWI) (*b*-value of 400--500 or 800 s/mm^2^); 3) hypointensity on HBP; 4) fat content on T1-weighted dual gradient-echo in-phase and out-of-phase imaging (Dual-GRE); 5) non-enhancing capsule; 6) hemorrhagic content; 7) nodule-in-nodule; and 8) mosaic appearance. Regarding the last four features, the sequence in which the feature was observed was specified for each nodule. Any between-reader discrepancies concerning the presence or absence of imaging features were resolved by consensus discussion.

The diagnosis of HCC was suspected when at least one of the eight imaging features was identified on T2WI, DWI, HBP, or Dual-GRE. Nodules with none of these features were considered as benign entities and their tentative diagnoses were given. To further explore the diagnostic performance for hepatic malignancy, the same provisional radiologic criteria for HCC was applied to indicate hepatic malignancy.

The nodules were then re-reviewed after two weeks on a full-sequence gadoxetic acid-enhanced MRI including dynamic enhancement, three non-contrast MRI sequences (T2WI, DWI, and Dual-GRE), and HBP by the same independent readers to diagnose HCC. The diagnosis was made when the arterial hyperenhancing-only nodules on MRI showed one of the eight imaging features described above, the nodules demonstrated the hallmarks of HCC (APHE and portal venous washout), or the nodules showed only portal venous washout ([@B1][@B2][@B4]).

Statistical Analysis
--------------------

Clinical characteristics were compared across patients with HCCs and non-HCCs (benign lesions and other malignant tumors) using a one-way analysis of variance with a post hoc Tukey\'s test (for continuous variables) or the χ^2^ test (for categorical variables). To determine the abbreviated MRI sequence most predictive of HCC, per-lesion sensitivity, specificity, and accuracy of the four MRI sequences alone or in combination with others were calculated and compared to each other and to those of the full-sequence gadoxetic acid-enhanced MRI using generalized estimating equations. In a subgroup analysis, per-lesion analyses were performed according to the size of the nodules (1--2 cm, or \< 1 cm). Diagnostic performance for hepatic malignancy was also evaluated by calculating the per-lesion sensitivity, specificity, and accuracy. A *p* value \< 0.05 was considered statistically significant. All statistical analyses were performed using SPSS Statistics for Windows, Version 21.0 (IBM Corp., Armonk, NY, USA) and R software, Version 3.5.1 (The R Foundation for Statistical Computing, Vienna, Austria).

RESULTS
=======

Patient Characteristics and Pathologic Diagnosis of Nodules
-----------------------------------------------------------

There were 99 men (74%) and 35 women (26%) with a mean age ± standard deviation of 56.8 ± 10.0 years (range, 30--82 years) in the study. Hepatitis B was the predominant cause of chronic liver disease (n = 115; 85.8%), followed by hepatitis C and alcoholic hepatitis. The clinical characteristics of 134 patients are summarized in [Table 1](#T1){ref-type="table"}.

Of 151 nodules (mean size, 1.2 cm; range, 0.5--2 cm), 78 nodules from 75 patients were histopathologically diagnosed by either hepatic resection (n = 75), or core-needle biopsy (n = 3) to include 68 HCCs, eight combined hepatocellular cholangiocarcinoma (cHCC-CC), one dysplastic nodule (DN), and one focal nodular hyperplasia (FNH). Of them, 13 HCCs and one DN showed equivocal washout (9.3%). The remaining 73 benign lesions, including 69 AP shunts, two DNs, and two FNHs, were diagnosed based on typical imaging features and stability during a follow-up period of at least 18 months ([@B7][@B17]). There was a significant difference in the mean size of the nodules between patients with and without HCC (*p* \< 0.05).

Prevalence of MRI Features in HCC and Benign Entities
-----------------------------------------------------

The prevalence of the eight MRI features in HCC and benign lesions according to their size are shown in [Table 2](#T2){ref-type="table"}. In the 68 HCCs, diffusion restriction (n = 62; 91.2%), hypointensity on HBP (n = 63; 92.6%), and mild-to-moderate hyperintensity on T2WI (n = 59; 86.8%) were the three most common imaging features followed by fat deposition (n = 11; 16.2%). All eight MRI features were significantly more common in HCC (all *p* \< 0.05).

Diagnostic Performance of Abbreviated MRI for HCC
-------------------------------------------------

The per-lesion diagnostic performance of abbreviated MRI for HCC is shown in [Table 3](#T3){ref-type="table"} and [Supplementary Table 1](#S1){ref-type="supplementary-material"}. Among various combinations of four MRI sequences, the combination of T2WI, DWI, and Dual-GRE ([Figs. 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}) for detecting two or more MRI features showed acceptably high accuracy (89.4%), specificity (90.4%), and sensitivity (88.2%). Conversely, the combination of all four sequences resulted in the lowest specificity (84.3%) but slightly higher sensitivity (91.2%). There was no significant difference in the sensitivity, specificity, or accuracy between combinations (all *p* \> 0.05). Of note, in the subgroup analysis, sensitivities were lower in HCCs smaller than 1 cm across all sequences except for the combination of HBP and Dual-GRE.

In full-sequence gadoxetic acid-enhanced MRI, per-lesion sensitivity, specificity, and accuracy for HCC diagnosis were 92.7%, 86.8%, and 89.4%, respectively, comparable to those of non-contrast MRI with or without HBP (all *p* \> 0.05). On dynamic enhancement, of 68 HCCs, 36 (52.9%) showed hallmarks of HCC, 25 (36.8%) showed APHE only, and two (2.9%) showed washout only. Considering the equivalent diagnostic performance, non-contrast MRI composed of T2WI, DWI, and Dual-GRE could be the best-performing sequential imaging study, comparable to a full-sequence MRI.

Eight cHCC-CC, three AP shunts, two DNs, and two FNHs ranging 1--1.3 cm were falsely diagnosed as HCC. All cHCC-CCs showed mild to moderate hyperintensity on T2WI, diffusion restriction, and hypointensity on HBP, indicating HCC per the predefined diagnostic criteria. Two DNs, one AP shunt, and one FNH showed hypointensity on HBP, and the remaining two AP shunts and one FNH demonstrated mild to moderate hyperintensity on T2WI. In terms of false-negative diagnoses, three HCCs ranging 1--1.1 cm failed to demonstrate any of the eight MRI features and were subsequently not diagnosed as HCC. Upon review of their full-sequence MRI studies, dynamic enhancement using gadoxetic acid did not demonstrate washout either on portal venous phase or transitional phase, leading them to be missed even in the full-sequence MRI.

Diagnostic Performance of Abbreviated MRI for Hepatic Malignancy
----------------------------------------------------------------

The per-lesion performance of abbreviated MRI in diagnosing hepatic malignancy is shown in [Table 4](#T4){ref-type="table"} and [Supplementary Table 2](#S2){ref-type="supplementary-material"}. Combining Dual-GRE with HBP resulted in the highest accuracy (94.7%), sensitivity (94.7%), and specificity (94.7%) in the detection of at least one MRI feature deemed to indicate hepatic malignancy. To detect two or more MRI features, the combination of T2WI, DWI, and Dual-GRE resulted in a sensitivity, specificity, and accuracy of 86.8%, 97.3%, and 92.1%, respectively. There was no significant difference in the sensitivity, specificity, or accuracy between sequences (all *p* \> 0.05).

DISCUSSION
==========

Our study demonstrated that sequential non-contrast MRI comprising T2WI, DWI, and Dual-GRE has reasonable and comparable performance to full-sequence gadoxetic acid-enhanced MRI for diagnosing HCC and hepatic malignancies in indeterminate arterial-enhancing nodules smaller than 2 cm detected on multiphasic CT in patients at risk of HCC. With this, non-contrast MRI could be used as a sequential radiological examination to characterize arterial hypervascular nodules that require further assessment.

The best-performing combination of non-contrast sequences had comparable sensitivity, specificity, and accuracy to combinations added with HBP and to those of full-sequence gadoxetic acid-enhanced MRI in current and previous studies, reporting sensitivity, specificity, and accuracy of 76.0--91.9%, 81.2--93.6%, and 82.7%, respectively ([@B14][@B18][@B19][@B20]). Of note, on dynamic enhancement MRI, 36 (52.9%) of 68 HCCs showed APHE and portal venous washout, while two (2.9%) showed portal venous washout only. These results indicate that additional dynamic enhancement MRI could reveal hallmarks of HCC in some of the indeterminate nodules. However, given the comparable diagnostic performance of non-contrast MRI, our suggested diagnostic scheme still may play a potential role as sequential imaging after multiphasic CT in place of full-sequence MRI.

We used provisional diagnostic criteria of HCC and showed their future validity as formal criteria for multiphasic CT integrated with abbreviated MRI. Using LI-RADS v2018, and assuming that the nodules lacked threshold growth, the majority of HCCs in our study would be categorized as "probably HCC (LR-4)" but never "definite HCC (LR-5)" because ancillary features cannot upgrade an observation to definite HCC ([@B4]). The updated KLCA-NCC guideline opened a potential diagnostic pathway for abbreviated MRI by introducing "probable HCC" to specify nodules having some of the hallmarks of HCC and at least one of the ancillary features ([@B5]). Although the definition mostly fits our diagnostic criteria, it still refers to "probable HCC" instead of "definite HCC", incongruous with the results of the current study. Further study could establish the diagnostic criteria for abbreviated MRI alone or in combination with multiphasic CT.

In studies assessing the performance of gadoxetic acid-enhanced MRI in HCC diagnosis, HBP improved sensitivity at the cost of specificity ([@B14][@B21][@B22]). Similarly, HBP alone or in combination with other sequences increased the sensitivity by 3%, while decreasing the specificity up to 6% compared to the combination of all three non-contrast sequences in overall nodules, though without statistical significance. Specificity-wise, of 15 nodules falsely diagnosed as HCCs, 12 nodules showed hypointensity on HBP either with or without T2 hyperintensity or diffusion restriction. Considering the cost and medical resources required for HBP, non-contrast MRI may be a feasible sequential examination that could reduce the healthcare budget while preserving the diagnostic performance necessary for HCC. However, in nodules smaller than 1 cm, HBP increased the sensitivity by approximately 13% without compromising the specificity. Gadoxetic acid significantly improves the sensitivity for small (\< 2 cm) HCCs because it has a high lesion-to-background contrast ratio on HBP ([@B21][@B23][@B24]). Similar benefits may have contributed to the remarkable boost in sensitivity for HCC in smaller nodules. Thus, HBP might still be necessary when characterizing CT-detected nodules smaller than 1 cm.

In our study, eight cHCC-CCs were falsely diagnosed as HCC by both readers, majorly jeopardizing the specificity for HCC diagnosis, corroborated by the 7--8% increase in specificity for diagnosing hepatic malignancy that includes both HCC and cHCC-CC. Notably, one of the readers interpreted two such nodules as showing rim APHE, which is considered a feature suggesting non-HCC malignancy (LR-M) according to LI-RADS v2018 ([@B4]). Current LI-RADS does not permit integrated interpretation across modalities and thus assigning LI-RADS categories to our proposed combination of multiphasic CT and abbreviated non-contrast MRI is not valid for now ([@B25]). However, selectively adopting features suggesting non-HCC entities would likely increase the specificity for HCC diagnosis.

The present study has several limitations. First, it was a retrospective study, which has an inherent selection bias, and a prospective study is required for validation of the results; based on our exclusion criteria, many nodules were exempted from the final analysis, which may have led to a greater selection bias. Specifically, AP shunts were excluded based on their typical appearance on CT. However, because we intended to reflect actual clinical practice, which usually disregards typical AP shunts but pays full attention to atypical nodular AP shunts not to misdiagnose HCCs, we believe such an exclusion is justified. Additionally, many benign nodules including two DNs were diagnosed and included based on imaging features and stability over follow-up. To fully adopt non-contrast MRI as a sequential imaging, a prospective study including populations with and without a history of HCC is needed. Second, the performance of adding non-contrast MRI was not directly compared with those of other imaging methods, including multiphasic MRI using extracellular gadolinium contrast agent. Third, CT and MRI parameters varied between centers and that may have affected the diagnostic performance. Furthermore, the tissue signal of the liver on Dual-GRE and non-contrast T1-weighted image may be inconsistent across different field strengths ([@B26]). However, this is an innate limitation of multicenter, cross-platform studies. Finally, we did not evaluate other incidental lesions discovered on reviewing MRI sequences. Hence, we may have underestimated the performance of HBP. However, it was beyond the scope of this study to evaluate such lesions.

In conclusion, non-contrast MRI comprising T2WI, DWI, and Dual-GRE could be sequentially used to distinguish HCC in CT-detected indeterminate arterial-enhancing nodules in at-risk patients and can be potentially used for sequential imaging in place of a full-sequence MRI. In nodules smaller than 1 cm, HBP may still be needed to preserve the sensitivity.
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###### Supplementary Table 1

Per-Lesion Diagnostic Performance for HCC Using Abbreviated MRI Sequences according to Lesion Size

###### Supplementary Table 2

Per-Lesion Diagnostic Performance of Abbreviated MRI Sequence(s) for Hepatic Malignancy according to Size of Lesion

![Patient flow diagram.\
AP = arterioportal, CT = computed tomography, HCC = hepatocellular carcinoma, MRI = magnetic resonance imaging](kjr-21-280-g001){#F1}

![HCC in 55-year-old man with chronic hepatitis B.\
Multiphasic CT revealed 1.8-cm arterial enhancing nodule (arrowhead) in segment 8 of liver **(A)**, with no washout in portal venous phase **(B)** or in 3-minute delayed phase **(C)**. On T2-weighted image, nodule (arrowhead) shows mildly high signal intensity **(D)**, with diffusion restrictions (arrowheads) **(E, F)** (b = 800 s/mm^2^) and without any fat component on T1-weighted dual gradient-echo images **(G, H)**. This nodule was correctly diagnosed as HCC by combining non-contrast MRI.](kjr-21-280-g002){#F2}

![Arterioportal shunt in 48-year-old man with chronic hepatitis B.\
Multiphasic CT revealed 1.9-cm arterial enhancing nodule in segment 8 of liver (arrowhead) **(A, B)**, with no washout in portal venous phase **(C)** or in 3-minute delayed phase **(D)**. There is no high signal intensity in matching area on T2-weighted image **(E)**, no diffusion restriction **(F, G)** (b = 800 s/mm^2^), and no fat component on T1-weighted dual gradient-echo images **(H, I)**. The nodule was correctly diagnosed as non-HCC by combining non-contrast MRI.](kjr-21-280-g003){#F3}

###### Clinical Characteristics of Study Patients

![](kjr-21-280-i001)

  Characteristics             All Patients (151 Nodules)   Patients with HCC (68 Nodules)   Patients with Non-HCC (n = 83)   *P*           
  --------------------------- ---------------------------- -------------------------------- -------------------------------- ------------- --------------
  No. of patients             134                          65                               61                               8             
  Age (years)                 56.8 ± 10.0                  57.5 ± 9.4                       55.6 ± 10.9                      52.5 ± 6.5    0.395
  Sex (male/female)           99/35                        44/21                            51/10                            4/4           0.036
  Mean nodule size (cm)       1.2 ± 0.3                    1.3 ± 0.3                        1.1 ± 0.3                        1.4 ± 0.2     \< 0.001^\*^
  Causes of cirrhosis                                                                                                                      0.200
   Hepatitis B                115 (85.8)                   60 (92.3)                        47 (77.0)                        8 (100)       
   Hepatitis C                7 (5.2)                      1 (1.5)                          6 (9.8)                          0 (0)         
   Hepatitis B, C             1 (0.7)                      1 (1.5)                          0 (0)                            0 (0)         
   Alcoholic liver disease    7 (5.2)                      1 (1.5)                          6 (9.8)                          0 (0)         
   Other                      4 (3.0)                      2 (3.1)                          2 (3.3)                          0 (0)         
  Child-Pugh classification                                                                                                                0.144
   A                          118 (88.1)                   60 (92.3)                        51 (83.6)                        7 (87.5)      
   B                          13 (9.7)                     2 (3.1)                          10 (16.4)                        1 (12.5)      
   C                          3 (2.2)                      3 (4.6)                          0 (0)                            0 (0)         
  Tumor marker value                                                                                                                       
   AFP (ng/mL)                48.7 ± 158.2                 69.4 ± 202.7                     31.7 ± 103.3                     17.8 ± 21.4   0.334
   PIVKA-II                   31.9 ± 36.1                  32.4 ± 37.4                      27.1 ± 17.6                      41.6 ± 59.8   0.628

Otherwise specified, data in parentheses are percentage. ^\*^Significant difference between HCC and benign lesion. AFP = alpha fetoprotein, HCC = hepatocellular carcinoma, PIVKA-II = protein-induced by vitamin K absence or antagonist-II

###### Prevalence of Various Imaging Features of CT-Detected Indeterminate Arterial Enhancing Nodules according to Pathology and Size

![](kjr-21-280-i002)

  Imaging Features                    HCC        Benign Lesions   *P*                                      
  ----------------------------------- ---------- ---------------- ----------- ------- ---------- --------- ----------
  Diffusion restriction               6 (75.0)   56 (93.3)        62 (91.2)   0 (0)   3 (6.3)    3 (4.0)   \< 0.001
  Moderate high T2 signal             6 (75.0)   53 (88.3)        59 (86.8)   0 (0)   5 (10.6)   5 (6.7)   \< 0.001
  Fat deposition                      2 (25.0)   9 (15.0)         11 (16.2)   0 (0)   1 (2.1)    1 (1.3)   0.001
  Non-enhancing capsule               0 (0)      2 (3.3)          2 (2.9)     0 (0)   1 (2.1)    1 (1.3)   0.012
  Nodule in nodule appearance         0 (0)      1 (1.7)          1 (1.5)     0 (0)   0 (0)      0 (0)     0.019
  Mosaic appearance                   0 (0)      1 (1.7)          1 (1.5)     0 (0)   0 (0)      0 (0)     0.019
  Blood product                       0 (0)      1 (1.7)          1 (1.5)     0 (0)   0 (0)      0 (0)     0.019
  Hepatobiliary phase hypointensity   7 (87.5)   56 (93.3)        63 (92.6)   0 (0)   4 (8.5)    4 (5.3)   \< 0.001

Data represent number of nodules, while those in parentheses are percentages.

###### Per-Lesion Diagnostic Performance of Abbreviated MRI Sequence(s) for HCC

![](kjr-21-280-i003)

  Diagnostic Criteria                         Sensitivity (%)^\*^   *P*^†^               Specificity (%)^\*^   *P*^†^               Accuracy (%)^\*^      *P*^†^
  ------------------------------------------- --------------------- -------------------- --------------------- -------------------- --------------------- -----------------
  One or more findings^∥^                                                                                                                                 
   T2WI                                       86.8 \[76.4--94.7\]   0.347^‡^             84.3 \[74.7--91.4\]   All \> 0.990^‡^      86.0 \[79.4--91.1\]   All \> 0.910^‡^
   DWI                                        91.2 \[81.8--96.7\]   0.407^‡^             88.0 \[79.0--94.1\]                        89.4 \[83.4--93.8\]   
   HBP                                        92.7 \[83.7--97.6\]   0.701^‡^             85.5 \[76.1--92.3\]                        88.7 \[82.6--93.3\]   
   T2WI, Dual-GRE                             89.7 \[79.9--95.8\]   0.550^‡^             84.3 \[74.7--91.4\]                        86.8 \[80.3--91.7\]   
   DWI, Dual-GRE                              94.1 \[85.6--98.4\]   0.756^‡^             86.8 \[77.5--93.2\]                        90.1 \[84.2--94.3\]   
   HBP, Dual-GRE                              94.1 \[85.6--98.4\]                        85.5 \[76.1--92.3\]                        89.4 \[83.4--93.8\]   
  Two or more findings                                                                                                                                    
   T2WI, HBP                                  86.8 \[76.4--93.8\]   0.609^§^             88.0 \[79.0--94.1\]   All \> 0.970^§^      87.4 \[81.1--92.3\]   All \> 0.980^§^
   DWI, HBP                                   89.7 \[79.9--95.8\]   0.774^§^             89.2 \[80.4--94.9\]                        89.4 \[83.4--93.8\]   
   T2WI, DWI                                  85.3 \[74.6--92.7\]   0.512^§^             90.4 \[81.9--95.8\]                        88.1 \[81.8--92.8\]   
   T2WI, DWI, Dual-GRE                        88.2 \[78.1--94.8\]   0.744^§^             90.4 \[81.9--95.8\]                        89.4 \[83.4--93.8\]   
   T2WI, DWI, Dual-GRE, HBP                   91.2 \[81.8--96.7\]                        84.3 \[74.7--91.4\]                        87.4 \[81.1--92.3\]   
  Full-sequence gadoxetic acid-enhanced MRI   92.7 \[83.7--97.6\]   \> 0.990^¶,\ \*\*^   86.8 \[77.5--93.2\]   \> 0.990^¶,\ \*\*^   89.4 \[83.4--93.8\]   \> 0.990^\*\*^

Number in square brackets are 95% confidence intervals. ^\*^Percentage out of 151 nodules, ^†^Bonferroni-correct *p* values, ^‡^Compared to combination of HBP and Dual-GRE, ^§^Compared to combination of all four sequences, ^∥^Phrase "One or more findings" refers to presence of more than one finding among eight imaging features, known to favor diagnosis of HCC, ^¶^Compared to combination of T2WI, DWI, and Dual-GRE, ^\*\*^Compared to combination of T2WI, DWI, Dual-GRE, and HBP. Dual-GRE = dual gradient-echo in-phase and out-of-phase imaging, DWI = diffusion-weighted imaging, HBP = hepatobiliary phase imaging, T2WI = T2-weighted imaging

###### Per-Lesion Diagnostic Performance of Abbreviated MRI Sequence(s) for Hepatic Malignancy

![](kjr-21-280-i004)

  Diagnostic Criteria         Sensitivity (%)^\*^   *P*^†^     Specificity (%)^\*^   *P*^†^            Accuracy (%)^\*^      *P*^†^
  --------------------------- --------------------- ---------- --------------------- ----------------- --------------------- ----------
  One or more findings^∥^                                                                                                    
   T2WI                       86.8 \[77.1--93.5\]   0.296^‡^   92.0 \[83.4--97.0\]   All \> 0.950^‡^   89.4 \[83.4--93.8\]   0.470^‡^
   DWI                        90.8 \[81.9--88.8\]   0.359^‡^   96.0 \[88.8--99.2\]                     93.4 \[88.2--96.8\]   0.595^‡^
   HBP                        93.4 \[85.3--97.8\]   0.709^‡^   94.7 \[86.9--98.5\]                     94.0 \[89.0--97.2\]   0.835^‡^
   T2WI, Dual-GRE             89.5 \[80.3--95.3\]   0.434      92.0 \[83.4--97.0\]                     90.7 \[84.9--94.8\]   0.592
   DWI, Dual-GRE              93.4 \[85.3--97.8\]   0.508^‡^   94.7 \[86.9--98.5\]                     94.0 \[89.0--97.2\]   0.768^‡^
   HBP, Dual-GRE              94.7 \[87.1--98.6\]              94.7 \[86.9--98.5\]                     94.7 \[89.8--97.7\]   
  Two or more findings                                                                                                       
   T2WI, HBP                  86.8 \[77.1--93.5\]   0.544^§^   96.0 \[88.8--99.2\]   All \> 0.970^§^   91.4 \[85.7--95.3\]   0.721^§^
   DWI, HBP                   89.5 \[80.3--95.3\]   0.723^§^   97.3 \[90.7--99.7\]                     93.4 \[88.2--96.8\]   0.942^§^
   T2WI, DWI                  84.2 \[74.0--91.6\]   0.458^§^   97.4 \[90.7--99.7\]                     90.7 \[84.9--94.8\]   0.657^§^
   T2WI, DWI, Dual-GRE        86.8 \[77.1--93.5\]   0.610^§^   97.3 \[90.7--99.7\]                     92.1 \[86.5--95.8\]   0.831^§^
   T2WI, DWI, Dual-GRE, HBP   92.1 \[83.6--97.1\]              93.3 \[85.1--97.8\]                     92.7 \[87.3--96.3\]   

Numbers in square brackets are 95% confidence intervals. ^\*^Percentage out of 151 nodules, ^†^Bonferroni-correct *p* values, ^‡^Compared to combination of HBP and Dual-GRE, ^§^Compared to combination of all four sequences, ^∥^Phrase "One or more findings" refers to presence of more than one finding among eight imaging features, known to favor diagnosis of HCC.
